NO20052058L - Behandling av influensa. - Google Patents

Behandling av influensa.

Info

Publication number
NO20052058L
NO20052058L NO20052058A NO20052058A NO20052058L NO 20052058 L NO20052058 L NO 20052058L NO 20052058 A NO20052058 A NO 20052058A NO 20052058 A NO20052058 A NO 20052058A NO 20052058 L NO20052058 L NO 20052058L
Authority
NO
Norway
Prior art keywords
influenza
compositions
rnai
inhibiting
influenza virus
Prior art date
Application number
NO20052058A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052058D0 (no
Inventor
Jianzhu Chen
Herman N Eisen
Qing Ge
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of NO20052058D0 publication Critical patent/NO20052058D0/no
Publication of NO20052058L publication Critical patent/NO20052058L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Plant Pathology (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
NO20052058A 2002-09-28 2005-04-27 Behandling av influensa. NO20052058L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41445702P 2002-09-28 2002-09-28
US44637703P 2003-02-10 2003-02-10
PCT/US2003/030502 WO2004028471A2 (fr) 2002-09-28 2003-09-29 Therapeutique antigrippale

Publications (2)

Publication Number Publication Date
NO20052058D0 NO20052058D0 (no) 2005-04-27
NO20052058L true NO20052058L (no) 2005-06-28

Family

ID=32045286

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052058A NO20052058L (no) 2002-09-28 2005-04-27 Behandling av influensa.

Country Status (10)

Country Link
US (1) US20050008617A1 (fr)
EP (1) EP1658304A4 (fr)
JP (1) JP2006512906A (fr)
KR (1) KR20050084607A (fr)
AU (3) AU2003279010A1 (fr)
CA (1) CA2500468A1 (fr)
HK (1) HK1104302A1 (fr)
MX (1) MXPA05003287A (fr)
NO (1) NO20052058L (fr)
WO (2) WO2004028471A2 (fr)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080281041A1 (en) * 1999-06-07 2008-11-13 Rozema David B Reversibly Masked Polymers
US8541548B2 (en) * 1999-06-07 2013-09-24 Arrowhead Madison Inc. Compounds and methods for reversible modification of biologically active molecules
US8008355B2 (en) * 2002-03-11 2011-08-30 Roche Madison Inc. Endosomolytic poly(vinyl ether) polymers
US8138383B2 (en) * 2002-03-11 2012-03-20 Arrowhead Madison Inc. Membrane active heteropolymers
DE10214983A1 (de) * 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
AU2003268531A1 (en) 2002-09-06 2004-03-29 University Of South Florida Materials and methods for treatment of allergic diseases
US20060160759A1 (en) * 2002-09-28 2006-07-20 Jianzhu Chen Influenza therapeutic
US8145436B2 (en) 2003-07-15 2012-03-27 The Trustees Of The University Of Pennsylvania Method and systems for identifying micro-RNA targets and synthesizing novel micro-RNAs and uses of the same
US20050256071A1 (en) * 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
EP1649019A2 (fr) * 2003-07-15 2006-04-26 California Institute Of Technology Acides nucleiques inhibiteurs ameliores
WO2005026322A2 (fr) * 2003-09-11 2005-03-24 Clontech Laboratories, Inc. Produits de recombinaison codant arnic et procedes d'utilisation associes
EP1727556A2 (fr) * 2004-02-17 2006-12-06 University Of South Florida Materiaux et methodes permettant de traiter des troubles inflammatoires et lies a la proliferation cellulaire
JP2007523159A (ja) * 2004-02-20 2007-08-16 ジェネシス リサーチ アンド デベロップメント コーポレイション リミテッド Ｒｎａ干渉分子の標的送達
WO2005110438A2 (fr) * 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methodes et produits associes de liberation intracellulaire de polysaccharides
US20050265927A1 (en) * 2004-05-17 2005-12-01 Yale University Intranasal delivery of nucleic acid molecules
WO2006085987A2 (fr) * 2004-07-09 2006-08-17 University Of Iowa Research Foundation Arn interference dans des cellules epitheliales respiratoires
US20090313712A1 (en) * 2004-08-25 2009-12-17 Leandro Christmann RNA interference and disease resistance in avians
US20080222743A1 (en) * 2004-08-25 2008-09-11 Avigenics, Inc. RNA interference and disease resistance in avians
JP2008514202A (ja) * 2004-09-24 2008-05-08 ニュークレオニクス・インコーポレイテッド Ｒｎａｉによる一本鎖ウイルスの逆鎖複製中間体のターゲティング
US7790878B2 (en) 2004-10-22 2010-09-07 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
US20060089324A1 (en) * 2004-10-22 2006-04-27 Sailen Barik RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
US8691781B2 (en) 2004-11-05 2014-04-08 Sirnaomics, Inc. Compositions for treating respiratory viral infections and their use
US8138327B2 (en) * 2004-11-23 2012-03-20 City Of Hope Inducible systems and methods for controlling siRNA expression
CA2594334A1 (fr) 2005-01-07 2006-07-13 Alnylam Pharmaceuticals, Inc. Modulation d'arn interferent du virus respiratoire syncytial et utilisations therapeutiques de cette modulation
WO2006113679A2 (fr) 2005-04-15 2006-10-26 Board Of Regents, The University Of Texas System Administration d'arnsi par compositions lipidiques neutres
NZ560936A (en) * 2005-02-03 2010-04-30 Benitec Inc RNAI expression constructs
WO2006086345A2 (fr) * 2005-02-07 2006-08-17 The Trustees Of Columbia University In The City Of New York Methodes de traitement ou de prevention du cancer de la prostate hormono-resistant au moyen de petits arn interferents specifiques de la protocadherine-pc, ou d'autres inhibiteurs de l'expression ou de l'activite de la protocadherine-pc
US8008468B2 (en) * 2005-02-16 2011-08-30 Benitec, Inc. RNAi expression constructs with liver-specific enhancer/promoter
CA2603842A1 (fr) * 2005-04-08 2006-10-19 Nastech Pharmaceutical Company Inc. Arni therapeutique pour infection virale respiratoire
US20070213293A1 (en) * 2005-04-08 2007-09-13 Nastech Pharmaceutical Company Inc. Rnai therapeutic for respiratory virus infection
CN101277704A (zh) * 2005-04-12 2008-10-01 因特拉迪格姆公司 用于治疗癌症及其它新血管生成疾病的RNAi治疗剂的组合物和方法
CA2606002A1 (fr) * 2005-04-28 2006-11-02 Benitec Limited Cassettes d'expression d'arni multiples en vue de la delivrance simultanee d'agents d'arni associes a des motifs d'expression heterozygotes
US7199109B2 (en) * 2005-06-03 2007-04-03 Cal Poly Pomona Foundation Potent inhibition of influenza virus by specifically designed short interfering RNA
US20070031512A1 (en) * 2005-08-03 2007-02-08 Amcol International Corporation Virus-interacting layered phyllosilicates and methods of inactivating viruses
US20080184618A1 (en) * 2005-08-03 2008-08-07 Amcol International Virus-Interacting Layered Phyllosilicates and Methods of Use
US20100272769A1 (en) * 2005-08-03 2010-10-28 Amcol International Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
US20070099858A1 (en) * 2005-10-03 2007-05-03 Sirna Therapeutics, Inc. RNA interference mediated of inhibition of influenza virus gene expression using short interfering nucleic acid (siNA)
EP1934360A2 (fr) * 2005-10-14 2008-06-25 Nastech Pharmaceutical Company Inc. Composes et methodes pour l'obtention de particules de condensat d'acide ribonucleque de peptides pour therapie par arn
CA2627585A1 (fr) * 2005-11-01 2007-05-10 Alnylam Pharmaceuticals, Inc. Inhibition de la replication du virus de la grippe par interference arn
WO2007056153A2 (fr) * 2005-11-04 2007-05-18 Nastech Pharmaceutical Company Inc. Conjugues de peptide-arn substrat dicer utilises comme excipients d'administration pour arnsi
US20070218122A1 (en) * 2005-11-18 2007-09-20 Protiva Biotherapeutics, Inc. siRNA silencing of influenza virus gene expression
CN100365122C (zh) * 2005-12-30 2008-01-30 中国疾病预防控制中心病毒病预防控制所 针对乙型流感病毒多聚酶基因的siRNA序列及其应用
CN100365123C (zh) * 2005-12-30 2008-01-30 中国疾病预防控制中心病毒病预防控制所 针对乙型流感病毒膜蛋白基因的siRNA序列及其应用
CN100365121C (zh) * 2005-12-30 2008-01-30 中国疾病预防控制中心病毒病预防控制所 针对乙型流感病毒核壳蛋白基因的siRNA序列及其应用
FI20060246A0 (fi) 2006-03-16 2006-03-16 Jukka Westermarck Uusi kasvua stimuloiva proteiini ja sen käyttö
GB0605337D0 (en) 2006-03-17 2006-04-26 Genomica Sau Treatment of CNS conditions
CA2656990A1 (fr) * 2006-04-28 2007-11-08 University Of South Florida Matieres et procedes destines a reduire une inflammation par inhibition du recepteur du peptide natriuretique auriculaire
DK2037899T3 (da) * 2006-07-07 2011-05-09 Univ Aarhus Nanopartikler til nukleinsyreafgivelse
GB0613753D0 (en) * 2006-07-11 2006-08-23 Norwegian Radium Hospital Res Method
WO2008014404A2 (fr) * 2006-07-26 2008-01-31 The University Of Chicago Administration médiée par des récepteurs: compositions et méthodes
CA2661093A1 (fr) * 2006-08-18 2008-02-21 Nastech Pharmaceutical Company Inc. Conjugues de peptides et d'arn substrat de dicer et procedes de therapeutique par arn
KR101133799B1 (ko) * 2006-08-18 2012-04-24 에프. 호프만-라 로슈 아게 폴리뉴클레오타이드의 생체내 전달을 위한 다가접합체
US8017109B2 (en) * 2006-08-18 2011-09-13 Roche Madison Inc. Endosomolytic poly(acrylate) polymers
FI20060751A0 (fi) 2006-08-23 2006-08-23 Valtion Teknillinen Menetelmä prostatasyövän hoitoon ja mainitusta menetelmästä hyödyntävien potilaiden seulonta
US20100099737A1 (en) * 2006-08-24 2010-04-22 Gerald Krystal Compositions and methods for treating myelosuppression
KR100817024B1 (ko) * 2006-11-09 2008-03-26 재단법인 목암생명공학연구소 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물
EP2114983B8 (fr) 2007-02-07 2015-02-18 The Regents of the University of Colorado, A Body Corporate Inhibiteurs des recepteurs axl a activite tyrosine kinase et procedes de fabrication et d'utilisation de ceux-ci
CA2689042A1 (fr) * 2007-02-16 2008-08-28 Merck & Co., Inc. Compositions et methodes de potentialisation de l'activite de molecules biologiquement actives
JP2010521460A (ja) 2007-03-12 2010-06-24 アンティジェン・エクスプレス・インコーポレーテッド 癌免疫療法におけるＩｉ−ＲＮＡｉ関与Ｉｉ抑制
WO2008128176A1 (fr) * 2007-04-12 2008-10-23 Nucleonics, Inc. Polynucléotides de l'influenza, constructions d'expression, compositions et procédés d'utilisation
US8877917B2 (en) * 2007-04-23 2014-11-04 Alnylam Pharmaceuticals, Inc. Glycoconjugates of RNA interference agents
US20110209231A1 (en) * 2007-05-16 2011-08-25 Timothy James Doran Treatment and prevention of influenza
AU2008272051A1 (en) 2007-07-03 2009-01-08 Cytopathfinder, Inc. Treatment of influenza
CA2733676A1 (fr) 2007-08-10 2009-02-19 British Columbia Cancer Agency Branch Compositions de micro-arn et procedes pour traiter la leucemie myelogene
CN101367750B (zh) 2007-08-14 2012-05-23 中国人民解放军军事医学科学院毒物药物研究所 (1s,2s,3s,4r)-3-[(1s)-1-乙酰氨-2-乙基-丁基]-4-胍基-2-羟基-环戊基-1-羧酸水合物及其医药用途
NZ585784A (en) * 2007-12-13 2012-09-28 Alnylam Pharmaceuticals Inc siRNAs for the treatment and prevention of respiratory syncytial virus (RSV) infection
WO2010014755A1 (fr) * 2008-07-29 2010-02-04 The Regents Of The University Of Colorado Procédés et composés permettant d’optimiser le traitement contre le cancer
AU2009293658A1 (en) 2008-09-22 2010-03-25 James Cardia Reduced size self-delivering RNAi compounds
US20100168205A1 (en) * 2008-10-23 2010-07-01 Alnylam Pharmaceuticals, Inc. Methods and Compositions for Prevention or Treatment of RSV Infection Using Modified Duplex RNA Molecules
EP2355851B1 (fr) 2008-11-10 2018-04-04 Arbutus Biopharma Corporation Nouveaux lipides et nouvelles compositions pour l administration d agents thérapeutiques
US20100291188A1 (en) * 2008-12-04 2010-11-18 Musc Foundation For Research Development Periostin Inhibitory Compositions for Myocardial Regeneration, Methods of Delivery, and Methods of Using Same
WO2010078536A1 (fr) 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition de pcsk9 par arni
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
CA2755245A1 (fr) * 2009-03-13 2010-09-16 Egen, Inc. Compositions et procedes pour l'administration d'arn biologiquement actifs
FI20090161A0 (fi) 2009-04-22 2009-04-22 Faron Pharmaceuticals Oy Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä
AU2010247816B2 (en) 2009-05-12 2015-12-17 Romark Laboratories L.C. Haloalkyl heteroaryl benzamide compounds
ES2914949T3 (es) * 2009-06-26 2022-06-17 Romark Laboratories Lc Compuestos y métodos para tratar la gripe
DE102009031274A1 (de) 2009-06-30 2011-01-13 Justus-Liebig-Universität Giessen Liposomen zur pulmonalen Applikation
US8758996B2 (en) * 2009-09-21 2014-06-24 Intelligent Medical Devices, Inc. Optimized probes and primers and methods of using same for the binding, detection, differentiation, isolation and sequencing of influenza A; influenza B; novel influenza A/H1N1; and a novel influenza A/H1N1 RNA sequence mutation associated with oseltamivir resistance
EP3252068A3 (fr) 2009-10-12 2018-03-14 Larry J. Smith Procédés et compositions permettant de moduler l'expression génique à l'aide de médicaments à base d'oligonucléotides administrés in vivo ou in vitro
KR101605932B1 (ko) 2009-12-18 2016-03-24 노파르티스 아게 Ｈｓｆ1-관련 질환을 치료하기 위한 유기 조성물
JP2013519869A (ja) 2010-02-10 2013-05-30 ノバルティス アーゲー 筋肉成長のための方法および化合物
PL2539451T3 (pl) 2010-02-24 2016-08-31 Arrowhead Res Corporation Kompozycje do ukierunkowanego dostarczania siRNA
EP3431604A1 (fr) 2010-04-23 2019-01-23 Arrowhead Pharmaceuticals, Inc. Compositions organiques pour traiter des maladies associées à bêta-enac
PL2561078T3 (pl) 2010-04-23 2019-02-28 Cold Spring Harbor Laboratory Nowe, strukturalnie zaprojektowane shRNA
US20120244209A1 (en) 2011-03-02 2012-09-27 Roth Jack A Tusc2 therapies
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
FI20115640A0 (fi) 2011-06-22 2011-06-22 Turun Yliopisto Yhdistelmähoito
US20160032284A1 (en) 2011-09-02 2016-02-04 Arrowhead Research Corportation Organic compositions to treat hsf1-related diseases
FI20115876A0 (fi) 2011-09-06 2011-09-06 Turun Yliopisto Yhdistelmähoito
US20130122096A1 (en) * 2011-11-14 2013-05-16 Silenseed Ltd. Compositions for drug delivery and methods of manufacturing and using same
WO2013096958A1 (fr) * 2011-12-23 2013-06-27 Egen, Inc. Compositions et procédés pour l'administration d'arn biologiquement actifs
AU2013208720A1 (en) 2012-01-09 2014-07-24 Arrowhead Research Corporation RNAi agents to treat Beta-Catenin related diseases
EP3736333A1 (fr) 2012-05-02 2020-11-11 Arrowhead Pharmaceuticals, Inc. Compositions organiques pour traiter des maladies associées à kras
WO2014011512A1 (fr) * 2012-07-08 2014-01-16 Sirnaomics, Inc. Compositions et procédés pour des produits thérapeutiques arnsi « résistants » pour la grippe
WO2014009609A1 (fr) 2012-07-13 2014-01-16 Turun Yliopisto Trithérapie
CN103565745A (zh) 2012-08-10 2014-02-12 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
US9801953B2 (en) 2012-10-15 2017-10-31 Emory University Nanoparticles carrying nucleic acid cassettes for expressing RNA
CA2902393C (fr) 2013-02-28 2022-11-01 Arrowhead Research Corporation Compositions organiques destinees a traiter les maladies liees au gene epas1
US9693958B2 (en) 2013-03-15 2017-07-04 Cureport, Inc. Methods and devices for preparation of lipid nanoparticles
WO2015051135A2 (fr) 2013-10-04 2015-04-09 Novartis Ag Compositions organiques destinées au traitement de maladies associées à l'hepcidine
EP3169784B1 (fr) 2014-07-16 2020-06-10 Arrowhead Pharmaceuticals, Inc. Compositions d'arni pour le traitement de pathologies liées à l'apoc3
US20180010132A1 (en) 2014-09-11 2018-01-11 Novartis Ag Inhibition of prmt5 to treat mtap-deficiency-related diseases
WO2016065282A1 (fr) * 2014-10-24 2016-04-28 The Regents Of The University Of Michigan Formulation nasale, kit nasal, et procédé d'augmentation des taux nasaux d'oxyde nitrique (no)
US10479997B2 (en) 2014-12-01 2019-11-19 Novartis Ag Compositions and methods for diagnosis and treatment of prostate cancer
US20180296537A1 (en) 2015-06-05 2018-10-18 Novartis Ag Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
US9856481B2 (en) 2015-08-13 2018-01-02 Ann & Robert H. Lurie Children's Hospital MicroRNA treatment of fibrosis
EP3389650B1 (fr) 2015-12-18 2022-01-12 The Board of Regents of The University of Texas System Thérapeutiques pour la prise en charge du travail prématuré
KR101712856B1 (ko) * 2016-06-16 2017-03-07 재단법인 한국파스퇴르연구소 인플루엔자 바이러스의 복제에 관여하는 신규 인간 유전자 및 이의 용도
WO2018047148A1 (fr) 2016-09-12 2018-03-15 Novartis Ag Composés pour inhibition du miarn
US11278592B2 (en) 2016-10-12 2022-03-22 Board Of Regents, The University Of Texas System Methods and compositions for TUSC2 immunotherapy
US20180245065A1 (en) 2016-11-01 2018-08-30 Novartis Ag Methods and compositions for enhancing gene editing
EP3655004A2 (fr) 2017-07-21 2020-05-27 Novartis AG Compositions et procédés permettant de traiter un cancer
AU2018329190A1 (en) 2017-09-11 2020-04-23 Arrowhead Pharmaceuticals, Inc. RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
WO2019150309A1 (fr) 2018-02-02 2019-08-08 Hammack Scott Modulateurs de gpr68 et leurs utilisations pour le traitement et la prévention de maladies
US20210123016A1 (en) 2018-05-02 2021-04-29 Novartis Ag Regulators of human pluripotent stem cells and uses thereof
WO2020086701A1 (fr) 2018-10-24 2020-04-30 Codiak Biosciences, Inc. Procédés d'amélioration de la puissance d'électroporation
WO2020163705A1 (fr) 2019-02-08 2020-08-13 Board Of Regents, The University Of Texas System Exosomes contenant de la télomérase pour le traitement de maladies associées au vieillissement et à un dysfonctionnement d'organe lié à l'âge
WO2021160937A1 (fr) 2020-02-11 2021-08-19 Turun Yliopisto Thérapie de cancers ras-dépendants
WO2021211923A1 (fr) * 2020-04-16 2021-10-21 Pulmoquine Therapeutics, Inc. Composés et méthodes de traitement de maladies
KR20230005244A (ko) 2020-04-20 2023-01-09 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 생물학적 활성 건조 분말 조성물 및 이의 제조 및 사용 방법
US20230190871A1 (en) 2020-05-20 2023-06-22 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
US20230302154A1 (en) 2020-08-19 2023-09-28 The Board Of Regents Of The University Of Texas System Nanodrugs for targeted drug delivery and use thereof
US20230303665A1 (en) 2020-08-28 2023-09-28 Sana Biotechnology, Inc. Modified anti-viral binding agents
WO2023225160A1 (fr) 2022-05-18 2023-11-23 The Children's Hospital Of Philadelphia Compositions et procédés de régulation de l'épissage alternatif inductible de l'expression génique

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194428A (en) * 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US20020165183A1 (en) * 1999-11-29 2002-11-07 Hans Herweijer Methods for genetic immunization
DE19960206A1 (de) * 1999-12-14 2001-07-19 Frank Czubayko Komplexierung von RNS mit Polyethyleniminen zur deren Stabilisierung und zellulären Einschleusung
ATE450621T2 (de) * 2000-03-30 2009-12-15 Whitehead Biomedical Inst Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
CA2410566A1 (fr) * 2000-05-24 2001-11-29 University Of Massachusetts Transport intraflagellaire
US20020061861A1 (en) * 2000-08-17 2002-05-23 Hans Herweijer Nucleic acid expression from linear nucleic acids
US20020081736A1 (en) * 2000-11-03 2002-06-27 Conroy Susan E. Nucleic acid delivery
HU230458B1 (hu) * 2000-12-01 2016-07-28 Europäisches Laboratorium für Molekularbiologie (EMBL) Az RNS interferenciát közvetítő kis RNS molekulák
AU2002313699A1 (en) * 2001-07-20 2003-03-03 Ribozyme Pharmacuticals, Inc. Enzymatic nucleic acid peptide conjugates
US7101995B2 (en) * 2001-08-27 2006-09-05 Mirus Bio Corporation Compositions and processes using siRNA, amphipathic compounds and polycations
US20040162235A1 (en) * 2003-02-18 2004-08-19 Trubetskoy Vladimir S. Delivery of siRNA to cells using polyampholytes

Also Published As

Publication number Publication date
WO2004029213A2 (fr) 2004-04-08
AU2003279010A1 (en) 2004-04-19
EP1658304A4 (fr) 2009-01-14
WO2004029213A3 (fr) 2004-09-16
JP2006512906A (ja) 2006-04-20
AU2010202770A1 (en) 2010-07-22
WO2004028471A2 (fr) 2004-04-08
CA2500468A1 (fr) 2004-04-08
NO20052058D0 (no) 2005-04-27
AU2003279004B2 (en) 2009-10-08
WO2004028471A3 (fr) 2006-03-09
AU2003279004A1 (en) 2004-04-19
AU2003279010A8 (en) 2004-04-19
MXPA05003287A (es) 2005-07-05
EP1658304A2 (fr) 2006-05-24
KR20050084607A (ko) 2005-08-26
HK1104302A1 (en) 2008-01-11
US20050008617A1 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
NO20052058L (no) Behandling av influensa.
Khaitov et al. Silencing of SARS‐CoV‐2 with modified siRNA‐peptide dendrimer formulation
Zheng et al. Human microRNA hsa-miR-296-5p suppresses enterovirus 71 replication by targeting the viral genome
Gregory et al. Toll-like receptor signaling controls reactivation of KSHV from latency
CY1121894T1 (el) Θεραπεια hbv
NO20071953L (no) RNAi modulering av RSV, PIV og andre respiratoriske viruser og anvendelse derav
BRPI0416187A (pt) método de prevenir fusão de vìrus: célula inibindo a função da região de iniciação de fusão em vìrus de rna tendo proteìnas de envelope fusogênico de membrana da classe i
WO2006031901A3 (fr) Petits arn interferents inhibant efficacement l'expression genique virale et methodes d'utilisation associees
WO2007032794A3 (fr) Inhibition de l'expression genique virale a l'aide d'un petit arn interferent
McCaskill et al. RNA-mediated degradation of microRNAs: A widespread viral strategy?
PE20081215A1 (es) Identificacion y caracterizacion de variantes de replicon de vhc con menor susceptibilidad a vhc-796, y metodos relacionados
MXPA03000061A (es) Manipulacion de virus de arn encadenados negativos mediante redisposicion de sus genes y usos de los mismos.
Lin et al. MiR674 inhibits the neuraminidase-stimulated immune response on dendritic cells via down-regulated Mbnl3
Bub et al. Astrovirus replication is dependent on induction of double-membrane vesicles through a PI3K-dependent, LC3-independent pathway
SG136969A1 (en) Influenza therapeutic
Shen et al. Effective inhibition of porcine epidemic diarrhea virus by RNA interference in vitro
McCaskill et al. Potent inhibition of Hendra virus infection via RNA interference and poly I: C immune activation
Huang et al. RNA interference inhibits hepatitis E virus mRNA accumulation and protein synthesis in vitro
WO2021226019A3 (fr) Compositions et méthodes de traitement d'infections virales
EP3017046B1 (fr) Agents arni pour l'inhibition du virus du chikungunya
US11389526B2 (en) Self-attenuated prophylactic and therapeutic vaccines against pathogens
Chamberlain et al. The science of biodefense: RNAi
Ali et al. Suppressors of silencers: Exploring viral suppression of RNAi in emerging RNA viruses.
Rezza Prevention and control of emerging infections: a challenge for the 3rd millennium
MX2023011120A (es) Tratamiento de la infeccion por virus de arn con un inhibidor de citidina deaminasa.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application